---
schema_version: "secwatch.filing_event.v1"
accession: "0001178913-23-000679"
form_type: "8-K"
ticker: "CMMB"
cik: "0001534248"
company_name: "Chemomab Therapeutics Ltd."
filed_at: "2023-02-21T23:59:59+00:00"
generated_at: "2026-06-19T06:53:30.137686+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Chemomab receives FDA clearance to start Phase 2 trial of CM-101 in systemic sclerosis

## Summary
- FDA cleared IND for Phase 2 ABATE trial of CM-101 in systemic sclerosis (SSc).
- CM-101 is a first-in-class monoclonal antibody targeting CCL24; has Orphan Drug designation for SSc and PSC.
- Trial to enroll 45 patients; primary endpoint safety; top-line data expected H2 2024.
- CM-101 previously well-tolerated in early trials, reduced fibro-inflammatory biomarkers.

## SEC filing metadata
- accession: 0001178913-23-000679
- form_type: 8-K
- ticker: CMMB
- cik: 0001534248
- company_name: Chemomab Therapeutics Ltd.
- filed_at: 2023-02-21T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534248/000117891323000679/0001178913-23-000679-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534248/000117891323000679/form8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001178913-23-000679
- JSON: https://secwatch.observer/filing/0001178913-23-000679.json
- Plain text: https://secwatch.observer/filing/0001178913-23-000679.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.